No­var­tis heads to the fin­ish line with CDK 4/6 block­buster con­tender ri­bo­ci­clib

In the fi­nal stretch in its jour­ney to reg­u­la­tors, No­var­tis post­ed a pos­i­tive snap­shot of piv­otal Phase III da­ta on its CDK 4/6 con­tender ri­bo­ci­clib (LEE011), set­ting up a like­ly show­down with Pfiz­er in treat­ing breast can­cer.

The head­line fig­ure from ES­MO is that ri­bo­ci­clib com­bined with letro­zole re­duced the risk of death or pro­gres­sion by 44% among first-line pa­tients com­pared to letro­zole alone, of­fer­ing fur­ther en­cour­age­ment to the phar­ma gi­ant that it’s right on track to gain­ing an ap­proval for this drug next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.